đ° Full Story
Opinion pieces published in Australian outlets on Feb. 6â7, 2026 highlight a rising social-media narrative around so-called âOzempic neckâ and related labels (âOzempic face,â âOzempic arms/buttâ) tied to GLPâ1 drugs originally developed for type 2 diabetes and now widely prescribed for weight management.
The columnist, Hannah Vanderheide, argues these phrases are media buzzwords and aesthetic observations rather than clinically validated side effects.
Online content â especially on TikTok and Instagram â has amplified accounts of facial volume loss, sagging and loose skin, while cosmetic clinics market surgical fixes.
Experts note such changes commonly follow any rapid or significant weight loss and ageing.
The articles cite growing GLPâ1 use in Australia (around 500,000 people) and warn that the conversation often centers more on appearance and commercial opportunity than on patient health or evidence-based safety concerns.





đŹ Commentary